Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will sponsor and participate in Wonderland, the World's Leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, FL from November 3rd to the 5th
-Seelos' SLS-002 (intranasal racemic ketamine) is believed to be the only drug in the psychedelic class currently being developed specifically to treat the symptoms of suicidality associated with major depression.
-Seelos Senior Management will sponsor the Press Breakfast on Friday November 4th at 8:30am and take part in 2 panel discussions on Saturday November 5th.
NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will sponsor and participate in Wonderland, the World's Leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, FL from November 3rd to the 5th.
Seelos will sponsor the Press Breakfast with Seelos Therapeutics on Friday November 4th at 8:30am ET to discuss their SLS-002 (intranasal racemic ketamine) program, which is currently enrolling patients in Part 2 of the registration directed, randomized, double-blind, placebo-controlled clinical study. The purpose of the study is to evaluate the efficacy, safety, and tolerability of repeat doses of SLS-002, in addition to standard of care, on the symptoms of major depression and suicidality in patients who are assessed to be at an imminent risk of suicide.
